
The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network meta-analysis published online July 2 in JAMA Dermatology.
Amit Garg, M.D., from Northwell in New Hyde Park, New York, and colleagues compared the efficacy, safety, and tolerability of treatments for moderate-to-severe HS in a systematic literature review of phase 2 and 3 randomized clinical trials. Twenty-five trials, including 5,767 patients and 39 unique treatments, had available hidradenitis suppurativa clinical response (HiSCR)-50 data.
The researchers found that sonelokimab (120 mg every four weeks and 240 mg every two weeks), lutikizumab (300 mg every two weeks), adalimumab (40 mg once per week), bimekizumab (320 mg every two weeks and 320 mg every four weeks), povorcitinib (15 mg once a day), and secukinumab (300 mg every four weeks and 300 mg every two weeks) were associated with significantly higher HiSCR-50 response rates compared with placebo.
The differences between adalimumab (40 mg once per week) and other targeted treatments were mostly not statistically significant. The percentage of patients experiencing serious adverse events ranged from 0% to 10%, 0% to 8%, and 0% to 6% in the placebo groups, the adalimumab (40 mg once per week) groups, and the other active treatment groups, respectively.
“These data do not provide strong support for the superiority of one treatment over adalimumab, or vice versa,” the authors write.
More information:
Amit Garg et al, Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa, JAMA Dermatology (2025). DOI: 10.1001/jamadermatol.2025.1976
2025 HealthDay. All rights reserved.
Citation:
Review compares efficacy, safety of treatments for hidradenitis suppurativa (2025, July 7)
retrieved 7 July 2025
from https://medicalxpress.com/news/2025-07-efficacy-safety-treatments-hidradenitis-suppurativa.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network meta-analysis published online July 2 in JAMA Dermatology.
Amit Garg, M.D., from Northwell in New Hyde Park, New York, and colleagues compared the efficacy, safety, and tolerability of treatments for moderate-to-severe HS in a systematic literature review of phase 2 and 3 randomized clinical trials. Twenty-five trials, including 5,767 patients and 39 unique treatments, had available hidradenitis suppurativa clinical response (HiSCR)-50 data.
The researchers found that sonelokimab (120 mg every four weeks and 240 mg every two weeks), lutikizumab (300 mg every two weeks), adalimumab (40 mg once per week), bimekizumab (320 mg every two weeks and 320 mg every four weeks), povorcitinib (15 mg once a day), and secukinumab (300 mg every four weeks and 300 mg every two weeks) were associated with significantly higher HiSCR-50 response rates compared with placebo.
The differences between adalimumab (40 mg once per week) and other targeted treatments were mostly not statistically significant. The percentage of patients experiencing serious adverse events ranged from 0% to 10%, 0% to 8%, and 0% to 6% in the placebo groups, the adalimumab (40 mg once per week) groups, and the other active treatment groups, respectively.
“These data do not provide strong support for the superiority of one treatment over adalimumab, or vice versa,” the authors write.
More information:
Amit Garg et al, Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa, JAMA Dermatology (2025). DOI: 10.1001/jamadermatol.2025.1976
2025 HealthDay. All rights reserved.
Citation:
Review compares efficacy, safety of treatments for hidradenitis suppurativa (2025, July 7)
retrieved 7 July 2025
from https://medicalxpress.com/news/2025-07-efficacy-safety-treatments-hidradenitis-suppurativa.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.